These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 36604466)

  • 1. Effect of withdrawal of thyroid hormones versus administration of recombinant human thyroid-stimulating hormone on renal function in thyroid cancer patients.
    An YS; Lee J; Kim HK; Lee SJ; Yoon JK
    Sci Rep; 2023 Jan; 13(1):206. PubMed ID: 36604466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant human thyroid-stimulating hormone versus thyroid hormone withdrawal preparation for radioiodine ablation in differentiated thyroid cancer in children, adolescents and young adults.
    Schumm MA; Pyo HQ; Kim J; Tseng CH; Yeh MW; Leung AM; Chiu HK
    Clin Endocrinol (Oxf); 2021 Aug; 95(2):344-353. PubMed ID: 33704813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant human thyrotropin-aided versus thyroid hormone withdrawal-aided radioiodine treatment for differentiated thyroid cancer after total thyroidectomy: a meta-analysis.
    Tu J; Wang S; Huo Z; Lin Y; Li X; Wang S
    Radiother Oncol; 2014 Jan; 110(1):25-30. PubMed ID: 24485353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of recombinant human thyroid stimulating hormone on sustaining liver and renal function in thyroid cancer patients during radioactive iodine therapy.
    Lee SJ; Lee HY; Lee WW; Kim SE
    Nucl Med Commun; 2014 Jul; 35(7):727-32. PubMed ID: 24709982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant human thyrotropin versus thyroid hormone withdrawal in an Asian population.
    Tang CYL; Thang SP; Zaheer S; Kwan CK; Ng DC
    Endocrine; 2020 Jul; 69(1):126-132. PubMed ID: 32112240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radioiodine treatment of metastatic thyroid cancer: relative efficacy and side effect profile of preparation by thyroid hormone withdrawal versus recombinant human thyrotropin.
    Klubo-Gwiezdzinska J; Burman KD; Van Nostrand D; Mete M; Jonklaas J; Wartofsky L
    Thyroid; 2012 Mar; 22(3):310-7. PubMed ID: 22313411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of thyroid hormone withdrawal and recombinant human thyroid-stimulating hormone administration for adjuvant therapy in patients with intermediate- to high-risk differentiated thyroid cancer.
    Iizuka Y; Katagiri T; Ogura K; Inoue M; Nakamura K; Mizowaki T
    Ann Nucl Med; 2020 Oct; 34(10):736-741. PubMed ID: 32643022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-risk patients with differentiated thyroid cancer T4 primary tumors achieve remnant ablation equally well using rhTSH or thyroid hormone withdrawal.
    Bartenstein P; Calabuig EC; Maini CL; Mazzarotto R; Muros de Fuentes MA; Petrich T; Rodrigues FJ; Vallejo Casas JA; Vianello F; Basso M; Balaguer MG; Haug A; Monari F; Vaňó RS; Sciuto R; Magner J
    Thyroid; 2014 Mar; 24(3):480-7. PubMed ID: 24040896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of Thyroid Hormone Withdrawal and Recombinant Human Thyrotropin on Glomerular Filtration Rate During Radioiodine Therapy for Well-Differentiated Thyroid Cancer.
    Coura-Filho GB; Willegaignon J; Buchpiguel CA; Sapienza MT
    Thyroid; 2015 Dec; 25(12):1291-6. PubMed ID: 26446582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant human thyroid-stimulating hormone versus thyroid hormone withdrawal in the identification of metastasis in differentiated thyroid cancer with 131I planar whole-body imaging and 124I PET.
    Van Nostrand D; Khorjekar GR; O'Neil J; Moreau S; Atkins FB; Kharazi P; Mete M; Chennupati SP; Burman KD; Wartofsky L
    J Nucl Med; 2012 Mar; 53(3):359-62. PubMed ID: 22315442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of Levothyroxine With Recombinant Human Thyroid-Stimulating Hormone on Urinary Iodine Excretion Before Radioactive Iodine Administration.
    Fujimoto K; Hataya Y; Okubo M; Matsuoka N
    Endocr Pract; 2021 Oct; 27(10):1022-1027. PubMed ID: 33831554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant human TSH versus hypothyroidism. Cost-minimization-analysis in the follow-up care of differentiated thyroid carcinoma.
    Dietlein M; Busemeyer S; Kobe C; Schmidt M; Theissen P; Schicha H
    Nuklearmedizin; 2010; 49(6):216-24. PubMed ID: 20877918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant human thyroid stimulating hormone-assisted radioactive iodine remnant ablation in thyroid cancer patients at intermediate to high risk of recurrence.
    Hugo J; Robenshtok E; Grewal R; Larson S; Tuttle RM
    Thyroid; 2012 Oct; 22(10):1007-15. PubMed ID: 22873801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant human thyrotropin versus thyroid hormone withdrawal preparation for radioiodine ablation in differentiated thyroid cancer: Experience in a South Taiwanese medical center.
    Tsai JR; Wu ST; Chi SY; Yang YT; Chan YC; Lim LS; Chiew YEW; Chen WC; Chen YN; Chou CK
    Kaohsiung J Med Sci; 2023 Feb; 39(2):175-181. PubMed ID: 36448726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term outcomes of renal function after radioactive iodine therapy for thyroid cancer according to preparation method: thyroid hormone withdrawal vs. recombinant human thyrotropin.
    Cho YY; Kim SK; Jung JH; Hahm JR; Kim TH; Chung JH; Kim SW
    Endocrine; 2019 May; 64(2):293-298. PubMed ID: 30471053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radioactive iodine administered for thyroid remnant ablation following recombinant human thyroid stimulating hormone preparation also has an important adjuvant therapy function.
    Tuttle RM; Lopez N; Leboeuf R; Minkowitz SM; Grewal R; Brokhin M; Omry G; Larson S
    Thyroid; 2010 Mar; 20(3):257-63. PubMed ID: 20187781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal.
    Hänscheid H; Lassmann M; Luster M; Thomas SR; Pacini F; Ceccarelli C; Ladenson PW; Wahl RL; Schlumberger M; Ricard M; Driedger A; Kloos RT; Sherman SI; Haugen BR; Carriere V; Corone C; Reiners C
    J Nucl Med; 2006 Apr; 47(4):648-54. PubMed ID: 16595499
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant Human Thyrotropin Worsens Renal Cortical Perfusion and Renal Function in Patients After Total Thyroidectomy Due to Differentiated Thyroid Cancer.
    Saracyn M; Lubas A; Bober B; Kowalski Ł; Kapusta W; Niemczyk S; Wartofsky L; Kamiński G
    Thyroid; 2020 May; 30(5):653-660. PubMed ID: 31964314
    [No Abstract]   [Full Text] [Related]  

  • 19. Recombinant human thyrotropin in thyroid remnant ablation with 131-iodine in high-risk patients.
    Rosario PW; Xavier AC; Calsolari MR
    Thyroid; 2010 Nov; 20(11):1247-52. PubMed ID: 20950256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant Human Thyroid-Stimulating Hormone Versus Thyroid Hormone Withdrawal in
    Plyku D; Hobbs RF; Huang K; Atkins F; Garcia C; Sgouros G; Van Nostrand D
    J Nucl Med; 2017 Jul; 58(7):1146-1154. PubMed ID: 28104741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.